0 CHECKOUT

Versartis, Inc. - Product Pipeline Review - 2015

  • ID: 3169852
  • March 2015
  • 28 pages
  • Global Markets Direct
1 of 3

Versartis, Inc. - Product Pipeline Review - 2015

Summary

This, ‘Versartis, Inc. - Product Pipeline Review - 2015’, provides an overview of the Versartis, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Versartis, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables
List of Figures
Versartis, Inc. Snapshot
Versartis, Inc. Overview
Key Information
Key Facts
Versartis, Inc. - Research and Development Overview
Key Therapeutic Areas
Versartis, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Versartis, Inc. - Pipeline Products Glance
Versartis, Inc. - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Versartis, Inc. - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Versartis, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Versartis, Inc. - Drug Profiles
somatropin
Product Description
Mechanism of Action
R&D Progress
Undisclosed Drug
Product Description
Mechanism of Action
R&D Progress
VRS-859 + AMX-808
Product Description
Mechanism of Action
R&D Progress
Versartis, Inc. - Pipeline Analysis
Versartis, Inc. - Pipeline Products by Target
Versartis, Inc. - Pipeline Products by Route of Administration
Versartis, Inc. - Pipeline Products by Molecule Type
Versartis, Inc. - Pipeline Products by Mechanism of Action
Versartis, Inc. - Recent Pipeline Updates
Versartis, Inc. - Dormant Projects
Versartis, Inc. - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Versartis, Inc., Key Information
Versartis, Inc., Key Facts
Versartis, Inc. - Pipeline by Indication, 2015
Versartis, Inc. - Pipeline by Stage of Development, 2015
Versartis, Inc. - Monotherapy Products in Pipeline, 2015
Versartis, Inc. - Combination Treatment Modalities in Pipeline, 2015
Versartis, Inc. - Phase III, 2015
Versartis, Inc. - Phase I, 2015
Versartis, Inc. - Preclinical, 2015
Versartis, Inc. - Pipeline by Target, 2015
Versartis, Inc. - Pipeline by Route of Administration, 2015
Versartis, Inc. - Pipeline by Molecule Type, 2015
Versartis, Inc. - Pipeline Products by Mechanism of Action, 2015
Versartis, Inc. - Recent Pipeline Updates, 2015
Versartis, Inc. - Dormant Developmental Projects,2015

List of Figures
Versartis, Inc. - Pipeline by Top 10 Indication, 2015
Versartis, Inc. - Pipeline by Stage of Development, 2015
Versartis, Inc. - Monotherapy Products in Pipeline, 2015
Versartis, Inc. - Pipeline by Top 10 Target, 2015
Versartis, Inc. - Pipeline by Top 10 Route of Administration, 2015
Versartis, Inc. - Pipeline by Top 10 Molecule Type, 2015
Versartis, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.